Evidence map›Paper›PMID 38861869›Full record

ArticleEBioMedicine2024

Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination.

Stefan Gravenstein, Frank DeVone, Oladayo A Oyebanji, Yasin Abul, Yi Cao, Philip A Chan, Christopher W Halladay, James L Rudolph, Clare Nugent, Jürgen Bosch and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Stefan GravensteinWarren Alpert Medical School, Brown University, Providence, RI, USA; Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA; Center of Innovation in Long-Term Services and Supports, Veterans Administration (VA) Medical Center, Providence, RI, USA. Electronic address: stefan_gravenstein@brown.edu.
Frank DeVoneCenter of Innovation in Long-Term Services and Supports, Veterans Administration (VA) Medical Center, Providence, RI, USA.
Oladayo A OyebanjiCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Yasin AbulWarren Alpert Medical School, Brown University, Providence, RI, USA; Center of Innovation in Long-Term Services and Supports, Veterans Administration (VA) Medical Center, Providence, RI, USA.
Yi CaoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Philip A ChanWarren Alpert Medical School, Brown University, Providence, RI, USA; Rhode Island Department of Health, Providence, RI, USA.
Christopher W HalladayCenter of Innovation in Long-Term Services and Supports, Veterans Administration (VA) Medical Center, Providence, RI, USA.
James L RudolphWarren Alpert Medical School, Brown University, Providence, RI, USA; Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA; Center of Innovation in Long-Term Services and Supports, Veterans Administration (VA) Medical Center, Providence, RI, USA.
Clare NugentWarren Alpert Medical School, Brown University, Providence, RI, USA.
Jürgen BoschCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Christopher L KingCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Brigid M WilsonGeriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA.
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Elizabeth M WhiteDepartment of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA.
David H CanadayCase Western Reserve University School of Medicine, Cleveland, OH, USA; Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA. Electronic address: dxc44@case.edu.
Kevin W McConeghyDepartment of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA; Center of Innovation in Long-Term Services and Supports, Veterans Administration (VA) Medical Center, Providence, RI, USA. Electronic address: kevin_mcconeghy@brown.edu.

Funding

Non-inferiority study of adjuvanted vs. high dose flu vaccine in residents of long term careR01AI129709 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI CANADAY, DAVID H, GRAVENSTEIN, STEFAN · 2018 to 2021
$4.7M
Early Drivers of Humoral Immunity to SARS-CoV-2 InfectionsU01CA260539 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KING, CHRISTOPHER L · 2020 to 2024
$3.4M
BLRD VA I01 BX005507NCI NIH HHS U01 CA260539NIAID NIH HHS R01 AI129709
6 · The paper itself

Abstract

backgroundBivalent SARS-CoV-2 vaccines were developed to counter increasing susceptibility to emerging SARS-CoV-2 variants. We evaluated the durability of immunity and protection following first bivalent vaccination among nursing home residents.

methodsWe evaluated anti-spike and neutralization titers from blood in 653 community nursing home residents before and after each monovalent booster, and a bivalent vaccine. Concurrent clinical outcomes were evaluated using electronic health record data from a separate cohort of 3783 residents of Veterans Affairs (VA) nursing homes who had received at least the primary series monovalent vaccination. Using target trial emulation, we compared VA residents who did and did not receive the bivalent vaccine to measure vaccine effectiveness against infection, hospitalization, and death.

findingsIn the community cohort, Omicron BA.5 neutralization activity rose after each monovalent and bivalent booster vaccination regardless of prior infection history. Titers declined over time but six months post-bivalent vaccination, BA.5 neutralization persisted at detectable levels in 75% of infection-naive and 98% of prior-infected individuals. In the VA nursing home cohort, bivalent vaccine added effectiveness to monovalent booster vaccination by 18.5% for infection (95% confidence interval (CI) -5.6, 34.0%), and 29.2% for hospitalization or death (95% CI -14.2, 56.2%) over five months.

interpretationThe level of protection declined after bivalent vaccination over a 6 month period and may open a window of added vulnerability before the next updated vaccine becomes available, suggesting a subset of nursing home residents may benefit from an additional vaccination booster.

fundingCDC, NIH, VHA.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesNursing HomesSARS-CoV-2VaccinationAgedAged, 80 and overAntibodies, NeutralizingFemaleHumansImmunization, SecondaryMaleSpike Glycoprotein, CoronavirusVaccine EfficacyAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusAntibodiesCOVID-19EffectivenessLong-term careVaccine

Identifiers

PMID38861869
PMCPMC11215210

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.